Top Medical News
MRI/ultrasound fusion biopsy accurately detects PCa in men with intermediate PSA
19 Nov 2021
Fusion biopsy with magnetic resonance imaging and ultrasonography (MRI/US) is an efficient method of detecting clinically significant prostate cancer (csPCa) in biopsy-naïve men with prostate specific antigen (PSA) levels 4–10 ng/mL, a new study has found.
Low carbohydrate diet lowers risk of MetS, remnant cholesterol in prostate cancer
16 Nov 2021
A low carbohydrate diet (LCD) may substantially reduce the risk of metabolic syndrome (MetS) and remnant cholesterol in patients with prostate cancer, a recent study has shown.
Socioeconomic disparities seen in geospatial clusters of urothelial carcinoma
15 Nov 2021
Spatially related clusters of urothelial carcinoma (UC) appear to correlate with locoregional environmental exposures rather than tobacco exposure, suggests a study. Such clusters may also be associated with socioeconomic disparities.
Dose-reduced ARPI leads to inferior survival in CRPC patients
09 Nov 2021
Reduced-dose treatment with androgen receptor pathway inhibitors (ARPI) lead to poorer oncological outcomes relative to full-dose regimens in castration-resistant prostate cancer (CRPC), a recent study has found.
Chlormadinone prolongs active surveillance, maintains QoL in men with prostate cancer
Audrey Abella, 05 Nov 2021
Use of the oral antiandrogen chlormadinone at a low dose led to improvements in persistence rate of active surveillance (AS), PSA* and testosterone levels and prostate volume, and quality of life (QoL) in men with low-risk prostate cancer (PCa), the PROSAS study has shown.
RS-RARP confers better continence outcomes than conventional RARP
03 Nov 2021
In prostate cancer patients, retzius-sparing robotic-assisted radical prostatectomy (RS-RARP) yields better continence outcomes compared with conventional RARP, a recent study has found.
5-alpha reductase inhibitor exposure does not mar prostate cancer detection with MRI
30 Oct 2021
Long-term exposure to 5-alpha reductase inhibitors (5-ARIs) is not associated with impaired detection of significant cancer on magnetic resonance imaging (MRI) but appears to influence the ability of apparent diffusion coefficient (ADC) metrics to discriminate between lesions harbouring significant and benign cancers, reveals a study.
Special Reports
Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer
Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas. 
Conference Reports
Obesity may influence survival in metastatic castration-resistant prostate cancer
Roshini Claire Anthony, 08 Sep 2021

The obesity paradox, where obesity appears to confer a protective effect, was noted in metastatic castration-resistant prostate cancer (CRPC), with improved survival outcomes among obese patients with metastatic CRPC, according to a study from EAU21.

Outcomes of active surveillance for prostate cancer may vary with age
Roshini Claire Anthony, 07 Sep 2021

The benefits of active surveillance for prostate cancer appear to be greater in men diagnosed with low-risk prostate cancer at an older age, according to a study from Sweden.

MRI-targeted biopsy + new risk score cuts unnecessary biopsies in prostate cancer
Elvira Manzano, 07 Sep 2021
An MRI-targeted biopsy* plus a new risk score cuts unnecessary biopsies by half in men with positive MRI results and elevated PSA** levels in the STHLM3-MRI study. This benefit comes without missing clinically significant cancers, experts report at EAU 2021.
High urine cotinine levels may signal bladder cancer recurrence
Roshini Claire Anthony, 26 Aug 2021

High levels of cotinine in the urine of smokers who have undergone resection for non-muscle invasive bladder cancer (NMIBC) could be a sign of cancer recurrence, according to a study from Lebanon presented at EAU21.

AbobotulinumtoxinA cuts incontinence episodes in patients with NDOI
Audrey Abella, 20 Aug 2021
In individuals with neurogenic detrusor overactivity incontinence (NDOI) who were regularly undergoing clean intermittent catheterization, significant reductions of urinary incontinence episodes were seen following treatment with abobotulinumtoxinA (aboBoNT-A), according to a pooled analysis of two CONTENT studies presented at EAU 2021.
Botulinum toxin type A may reduce incontinence episodes
Audrey Abella, 19 Aug 2021
In a systematic review and meta-analysis of randomized controlled trials (RCTs) presented at EAU 2021, the use of botulinum toxin (BTX) type A in individuals with neurogenic detrusor overactivity (NDO) and idiopathic overactive bladder (iOAB) led to a reduction in incontinence episodes.
MV140 bacterial vaccine reduces UTI frequency in women
Elaine Soliven, 18 Aug 2021
The sublingual bacterial vaccine MV140 reduces the number of recurrent urinary tract infections (UTIs) in women, according to a European study presented at EAU21.